Cargando…

A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma.

Thirty-one patients with advanced renal carcinoma or malignant melanoma were treated in the first feasibility study of alpha-interferon (Roferon) and the new oral immunomodulating agent, Linomide. Linomide 5 mg or 10 mg p.o. daily was given for 2 weeks; alpha-interferon was then added at 3 MU s.c. t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mackean, M. J., Kerr, D., Lesko, M., Svedberg, A., Hansson, F., Jodrell, D., Cassidy, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063243/ https://www.ncbi.nlm.nih.gov/pubmed/9862573

Ejemplares similares

Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.
por: Vaz, F., et al.
Publicado: (1995)

Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants.
por: Ziche, M., et al.
Publicado: (1998)

Identification of Linomide Derivatives as Potential Anticancer Therapeutics using Molecular Docking Studies
por: Borges e Soares, Giselle A., et al.
Publicado: (2022)

Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.
por: Håkansson, A., et al.
Publicado: (1996)

Interferon-Alpha Decreases Cancer Stem Cell Properties and Modulates Exosomes in Malignant Melanoma
por: García-Ortega, María Belén, et al.
Publicado: (2023)

Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial
por: Dixon, S, et al.
Publicado: (2006)

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1990)

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review
por: Okuyama, Sonia, et al.
Publicado: (2010)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
por: Ravaud, A, et al.
Publicado: (1999)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

Evaluation of interferon alpha 2b as adjunctive therapy for conjunctival melanoma
por: Benage, Matthew J., et al.
Publicado: (2019)

Phase I study of pegylated interferon‐alpha‐2b as an adjuvant therapy in Japanese patients with malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2016)

Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma
por: Heise, Ruth, et al.
Publicado: (2016)

Expression of Estrogen Receptor Alpha in Malignant Melanoma
por: Rajabi, Parvin, et al.
Publicado: (2017)

Failure of high doses of alpha interferon to affect the growth of human carcinoma, melanoma, and myeloid leukaemia xenografts.
por: Clutterbuck, R. D., et al.
Publicado: (1983)

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
por: Hoffmann, R., et al.
Publicado: (1998)

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.
por: Mackean, M. J., et al.
Publicado: (1998)

Expression of Integrin Alpha10 Is Induced in Malignant Melanoma
por: Wenke, Ann-Kathrin, et al.
Publicado: (2007)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma
por: Suarez, Lorena P., et al.
Publicado: (2016)

Recurrent Pericarditis, an Unexpected Effect of Adjuvant Interferon Chemotherapy for Malignant Melanoma
por: Ashraf, Farhan, et al.
Publicado: (2016)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
por: Christofyllakis, Konstantinos, et al.
Publicado: (2021)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Interferon Alpha in Systemic Lupus Erythematosus
por: Niewold, Timothy B., et al.
Publicado: (2010)

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

IL28B Polymorphism Cannot Predict Response to Interferon Alpha Treatment in Patients with Melanoma
por: Probst, Martin, et al.
Publicado: (2014)

Evaluation of modified Interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer
por: Hochmann, Sarah, et al.
Publicado: (2018)

Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent
por: Hillyer, P, et al.
Publicado: (2013)

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1996)

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
por: Suarez-Kelly, Lorena P., et al.
Publicado: (2019)

Interferons Alpha, Beta, and Omega
por: Meager, Anthony
Publicado: (1998)

A Case of Malignant Melanoma with In-Transit Metastasis That Responded to Intravenous Infusion of Interferon-β
por: Arima, Masaru, et al.
Publicado: (2014)

Interferon and Interferon Inducers in the Treatment of Malignancies
por: Levy, Hilton B., et al.
Publicado: (1970)

A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma.
por: Bard, D. R., et al.
Publicado: (1990)

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995)

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
por: Kerr, D. J., et al.
Publicado: (1989)

Cellular immunity in human malignant melanoma and melanoma histology.
por: Cameron-Mowat, D. E., et al.
Publicado: (1973)

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
por: Punt, C. J., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_flgmqv8tcoano069tuhuck5gj5